D-161, a novel pyran-based triple monoamine transporter blocker: Behavioral pharmacological evidence for antidepressant-like action

European Journal of Pharmacology

Volumn 589, Issue 1-3, 2008, Pages 73-79

  Dutta, Aloke K ^a   Ghosh, Balaram ^a   Biswas, Swati ^a   Reith, Maarten E A ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Dopamine; Monoamine transporter; Norepinephrine; Serotonin

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; D 142; D 161; D 165; D 168; D 185; D 186; D 187; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; DOV 21947; DULOXETINE; FLUOXETINE; IMIPRAMINE; MONOAMINE TRANSPORTER BLOCKING AGENT; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PYRAN DERIVATIVE; RADIOLIGAND; REBOXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VANOXERINE; VENLAFAXINE;

AMINE TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DEPRESSION; DOPAMINE RELEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERANCE; FORCED SWIMMING TEST; LOW DRUG DOSE; MALE; MOLECULAR BIOLOGY; MONOAMINE METABOLISM; MONOAMINE RELEASE; MOUSE; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROTEIN BINDING; PYRANS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SYNAPTOSOMES;

EID: 47549097343     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.05.008     Document Type: Article

References (52)

1. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., Golden R.N., Martin P., Potter W.Z., and Richelson E. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56 (1995) 395-401
2. Baldessarini R.J. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed. (2006), McGraw-Hill, New York 443
3. Beasley Jr. C.M., Holman S.L., and Potvin J.H. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann. Clin. Psychiatry 5 (1993) 199-207
4. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur. Neuropsychopharmacol. 13 (2003) 57-66
5. Briner K., and Dodel R.C. New approaches to rapid onset antidepressants. Curr. Pharm. Des. 4 (1998) 291-302
6. Brunello N., Mendlewicz J., Kasper S., Leonard B., Montgomery S., Nelson J., Paykel E., Versiani M., and Racagni G. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur. Neuropsychopharmacol. 12 (2002) 461-475
7. Brunello N., Blier P., Judd L.L., Mendlewicz J., Nelson C.J., Souery D., Zohar J., and Racagni G. Noradrenaline in mood and anxiety disorders: basic and clinical studies. Int. Clin. Psychopharmacol. 18 (2003) 191-202
8. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
9. Cookson J. Side-effects of antidepressants. Br. J. Psychiatry (1993) 20-24 Suppl
10. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., and Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 11 (2000) 58-65
11. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23 (2002) 238-245
12. Cryan J.F., O'Leary O.F., Jin S.H., Friedland J.C., Ouyang M., Hirsch B.R., Page M.E., Dalvi A., Thomas S.A., and Lucki I. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8186-8191
13. D'Aquila P.S., Collu M., Gessa G.L., and Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol. 405 (2000) 365-373
14. Davidson R.J., Irwin W., Anderle M.J., and Kalin N.H. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am. J. Psychiatry 160 (2003) 64-75
15. Dilsaver S.C., Chen Y.W., Swann A.C., Shoaib A.M., and Krajewski K.J. Suicidality in patients with pure and depressive mania. Am. J. Psychiatry 151 (1994) 1312-1315
16. Dutta A.K., Zhang S., Kolhatkar R., and Reith M.E. Dopamine transporter as target for drug development of cocaine dependence medications. Eur. J. Pharmacol. 479 (2003) 93-106
17. Eshleman A.J., Carmolli M., Cumbay M., Martens C.R., Neve K.A., and Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther. 289 (1999) 877-885
18. Goldstein B.J., and Goodnick P.J. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J. Psychopharmacol. 12 (1998) S55-87
19. Hamner M.B., and Diamond B.I. Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: a pilot study. Psychiatry. Res. 64 (1996) 209-211
20. Humble M. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy. Acta Psychiatr. Scand. Suppl. 402 (2000) 28-36
21. Iversen L. Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol. Psychiatry 5 (2000) 357-362
22. Klimek V., Schenck J.E., Han H., Stockmeier C.A., and Ordway G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry 52 (2002) 740-748
23. Koch S., Hemrick-Luecke S.K., Thompson L.K., Evans D.C., Threlkeld P.G., Nelson D.L., Perry K.W., and Bymaster F.P. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45 (2003) 935-944
24. Lopez A.D., and Murray C.C. The global burden of disease, 1990-2020. Nat. Med. 4 (1998) 1241-1243
25. Mischoulon D., Nierenberg A.A., Kizilbash L., Rosenbaum J.F., and Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can. J. Psychiatry 45 (2000) 476-481
26. Montgomery S.A., Baldwin D.S., and Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J. Affect. Disord. 69 (2002) 119-140
27. Nemeroff C.B. Psychopharmacology of affective disorders in the 21st century. Biol. Psychiatry 44 (1998) 517-525
28. Nierenberg A.A., and Amsterdam J.D. Treatment-resistant depression: definition and treatment approaches. J. Clin. Psychiatry 51 Suppl 39-47 (1990) 48-50 discussion
29. Nierenberg A.A., Quitkin F.M., Kremer C., Keller M.B., and Thase M.E. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology 29 (2004) 1012-1018
30. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283 (1997) 1305-1322
31. Oxman T.E. Antidepressants and cognitive impairment in the elderly. J. Clin. Psychiatry. 57 Suppl 5 (1996) 38-44
32. Papakostas G.I. Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacol. 16 (2006) 391-402
33. Pinder R.M., and Wieringa J.H. Third-generation antidepressants. Med. Res. Rev. 13 (1993) 259-325
34. Popik P., Krawczyk M., Golembiowska K., Nowak G., Janowsky A., Skolnick P., Lippa A., and Basile A.S. Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677. Cell. Mol. Neurobiol. 26 (2006) 857-873
35. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
36. Roy A., Pickar D., Linnoila M., and Potter W.Z. Plasma norepinephrine level in affective disorders. Relationship to melancholia. Arch. Gen. Psychiatry 42 (1985) 1181-1185
37. Schloss P., and Williams D.C. The serotonin transporter: a primary target for antidepressant drugs. J. Psychopharmacol. 12 (1998) 115-121
38. Shank R.P., Gardocki J.F., Schneider C.R., Vaught J.L., Setler P.E., Maryanoff B.E., and McComsey D.F. Preclinical evaluation of McN-5707 as a potential antidepressant. J. Pharmacol. Exp. Ther. 242 (1987) 74-84
39. Shank R.P., Vaught J.L., Pelley K.A., Setler P.E., McComsey D.F., and Maryanoff B.E. McN-5652: a highly potent inhibitor of serotonin uptake. J. Pharmacol. Exp. Ther. 247 (1988) 1032-1038
40. Shaw A.M., Boules M., Zhang Y., Williams K., Robinson J., Carlier P.R., and Richelson E. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur. J. Pharmacol. 555 (2007) 30-36
41. Skolnick P., Popik P., Janowsky A., Beer B., and Lippa A.S. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur. J. Pharmacol. 461 (2003) 99-104
42. Skolnick P., Popik P., Janowsky A., Beer B., and Lippa A.S. "Broad spectrum" antidepressants: is more better for the treatment of depression?. Life Sci. 73 (2003) 3175-3179
43. Sporn J., Ghaemi S.N., Sambur M.R., Rankin M.A., Recht J., Sachs G.S., Rosenbaum J.F., and Fava M. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Clin. Psychiatry 12 (2000) 137-140
44. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl.) 85 (1985) 367-370
45. Strakowski S.M., McElroy S.L., Keck Jr. P.E., and West S.A. Suicidality among patients with mixed and manic bipolar disorder. Am. J. Psychiatry 153 (1996) 674-676
46. Tatsumi M., Groshan K., Blakely R.D., and Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340 (1997) 249-258
47. Vaishnavi S.N., Nemeroff C.B., Plott S.J., Rao S.G., Kranzler J., and Owens M.J. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol. Psychiatry 55 (2004) 320-322
48. Vida S., and Looper K. Precision and comparability of adverse event rates of newer antidepressants. J. Clin. Psychopharmacol. 19 (1999) 416-426
49. Zhang S., Reith M.E., and Dutta A.K. Design, synthesis, and activity of novel cis- and trans-3,6-disubstituted pyran biomimetics of 3,6-disubstituted piperidine as potential ligands for the dopamine transporter. Bioorg. Med. Chem. Lett. 13 (2003) 1591-1595
50. Zhang S., Zhen J., Reith M.E., and Dutta A.K. Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters. Bioorg. Med. Chem. 12 (2004) 6301-6315
51. Zhang S., Zhen J., Reith M.E., and Dutta A.K. Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner. J. Med. Chem. 48 (2005) 4962-4971
52. Zhang S., Fernandez F., Hazeldine S., Deschamps J., Zhen J., Reith M.E., and Dutta A.K. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters. J. Med. Chem. 49 (2006) 4239-4247